Marinus Pharmaceuticals (MRNS) Soars: Stock Adds 5.5% in Session
Marinus Pharmaceuticals, Inc. MRNS was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $1.77–$2.15 in the past one-month time frame, witnessed a sharp increase yesterday.
The stock gained after the company reported that it has entered into a five-year development contract with the Biomedical Advanced Research and Development Authority. The deal will support the development of IV ganaxolone for the treatment of refractory status epilepticus.
The company has seen three positive estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Marinus Pharmaceuticals. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Marinus Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Marinus Pharmaceuticals, Inc. Price
Marinus Pharmaceuticals, Inc. price | Marinus Pharmaceuticals, Inc. Quote
A better-ranked stock in the Medical - Drugs industry is Catalent, Inc. CTLT, holding a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Marinus Pharmaceuticals, Inc. (MRNS) : Free Stock Analysis Report
Catalent, Inc. (CTLT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
